The protein kinase C agonist prostratin induces differentiation of human myeloid leukemia cells and enhances cellular differentiation by chemotherapeutic agents.

[1]  Javier León,et al.  Myc and cell cycle control. , 2015, Biochimica et biophysica acta.

[2]  Neil Swanson,et al.  Ingenol mebutate gel for actinic keratosis. , 2012, The New England journal of medicine.

[3]  S. Lowe,et al.  RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia , 2011, Nature.

[4]  Ø. Bruserud,et al.  The protein kinase C agonist PEP005 increases NF‐κB expression, induces differentiation and increases constitutive chemokine release by primary acute myeloid leukaemia cells , 2009, British journal of haematology.

[5]  J. León,et al.  Inhibition of cell differentiation: A critical mechanism for MYC-mediated carcinogenesis? , 2009, Cell cycle.

[6]  D. Joseph-McCarthy,et al.  Identification, characterization and initial hit-to-lead optimization of a series of 4-arylamino-3-pyridinecarbonitrile as protein kinase C theta (PKCtheta) inhibitors. , 2008, Journal of medicinal chemistry.

[7]  Zhen-yi Wang,et al.  Acute promyelocytic leukemia: from highly fatal to highly curable. , 2008, Blood.

[8]  B. Edgar,et al.  Mechanisms controlling cell cycle exit upon terminal differentiation. , 2007, Current opinion in cell biology.

[9]  Rui Huang,et al.  Melissoidesin G, a diterpenoid purified from Isodon melissoides, induces leukemic‐cell apoptosis through induction of redox imbalance and exhibits synergy with other anticancer agents , 2007, International journal of cancer.

[10]  A. Friedman.  Transcriptional control of granulocyte and monocyte development , 2007, Oncogene.

[11]  A. Redig,et al.  The protein kinase C (PKC) family of proteins in cytokine signaling in hematopoiesis. , 2007, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[12]  D. Johnson,et al.  Signal transduction pathways that contribute to myeloid differentiation , 2007, Leukemia.

[13]  M. Kazanietz,et al.  Protein kinase C and other diacylglycerol effectors in cancer , 2007, Nature Reviews Cancer.

[14]  M. Hezareh.  Prostratin as a new therapeutic agent targeting HIV viral reservoirs. , 2005, Drug news & perspectives.

[15]  F. Khanim,et al.  PEP005, a selective small-molecule activator of protein kinase C, has potent antileukemic activity mediated via the delta isoform of PKC. , 2005, Blood.

[16]  W. Greene,et al.  Prostratin Antagonizes HIV Latency by Activating NF-κB* , 2004, Journal of Biological Chemistry.

[17]  M. Foti,et al.  Mechanisms of HIV Receptor and Co-Receptor Down-Regulation by Prostratin: Role of Conventional and Novel PKC Isoforms , 2004, Antiviral chemistry & chemotherapy.

[18]  C. Whitacre,et al.  Phase I and correlative study of combination bryostatin 1 and vincristine in relapsed B-cell malignancies. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[19]  R. Stone,et al.  The Difficult Problem of Acute Myeloid Leukemia in the Older Adult , 2002, CA: a cancer journal for clinicians.

[20]  Y. Korin,et al.  Effects of Prostratin on T-Cell Activation and Human Immunodeficiency Virus Latency , 2002, Journal of Virology.

[21]  De Johnson,et al.  Importance of MEK-1/-2 signaling in monocytic and granulocytic differentiation of myeloid cell lines , 2002, Leukemia.

[22]  M. Boyd,et al.  Prostratin: activation of latent HIV-1 expression suggests a potential inductive adjuvant therapy for HAART. , 2001, Blood.

[23]  J. Harbour,et al.  The Rb/E2F pathway: expanding roles and emerging paradigms. , 2000, Genes & development.

[24]  James M. Roberts,et al.  CDK inhibitors: positive and negative regulators of G1-phase progression. , 1999, Genes & development.

[25]  A. Conney,et al.  Effect of intravenous infusions of 12-O-tetradecanoylphorbol-13-acetate (TPA) in patients with myelocytic leukemia: preliminary studies on therapeutic efficacy and toxicity. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[26]  H Nagahara,et al.  Hypo-phosphorylation of the retinoblastoma protein (pRb) by cyclin D:Cdk4/6 complexes results in active pRb. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[27]  B. Hoffman,et al.  The proto-oncogene c-myc blocks myeloid differentiation independently of its target gene ornithine decarboxylase. , 1996, Blood.

[28]  Z. Szallasi,et al.  Bryostatin 1 protects protein kinase C-delta from down-regulation in mouse keratinocytes in parallel with its inhibition of phorbol ester-induced differentiation. , 1994, Molecular pharmacology.

[29]  F. Marks,et al.  Rottlerin, a novel protein kinase inhibitor. , 1994, Biochemical and biophysical research communications.

[30]  Z. Szallasi,et al.  Nonpromoting 12-deoxyphorbol 13-esters inhibit phorbol 12-myristate 13-acetate induced tumor promotion in CD-1 mouse skin. , 1993, Cancer research.

[31]  G. Martiny-Baron,et al.  Selective inhibition of protein kinase C isozymes by the indolocarbazole Gö 6976. , 1993, The Journal of biological chemistry.

[32]  Z. Szallasi,et al.  Non-promoting 12-deoxyphorbol 13-esters as potent inhibitors of phorbol 12-myristate 13-acetate-induced acute and chronic biological responses in CD-1 mouse skin. , 1992, Carcinogenesis.

[33]  Z. Szallasi,et al.  A nonpromoting phorbol from the samoan medicinal plant Homalanthus nutans inhibits cell killing by HIV-1. , 1992, Journal of medicinal chemistry.

[34]  Z. Szallasi,et al.  Prostratin, a nonpromoting phorbol ester, inhibits induction by phorbol 12-myristate 13-acetate of ornithine decarboxylase, edema, and hyperplasia in CD-1 mouse skin. , 1991, Cancer research.

[35]  H. Tilly,et al.  Low-dose cytarabine versus intensive chemotherapy in the treatment of acute nonlymphocytic leukemia in the elderly. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  A. Kraft,et al.  Varied differentiation responses of human leukemias to bryostatin 1. , 1989, Cancer research.

[37]  D. Kufe,et al.  Bryostatin 1 activates protein kinase C and induces monocytic differentiation of HL-60 cells. , 1988, Blood.

[38]  U. Pettersson,et al.  Phorbol ester-induced terminal differentiation is inhibited in human U-937 monoblastic cells expressing a v-myc oncogene. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[39]  M. Dell'aquila,et al.  Inhibition by bryostatin 1 of the phorbol ester-induced blockage of differentiation in hexamethylene bisacetamide-treated Friend erythroleukemia cells. , 1987, Cancer research.

[40]  A. Berrebi,et al.  Review of clinical and haematological response to low‐dose cytosine arabinoside in acute myeloid leukaemia , 1987, European journal of haematology.

[41]  J. Minta,et al.  In vitro induction of cytologic and functional differentiation of the immature human monocytelike cell line U-937 with phorbol myristate acetate. , 1985, The American journal of pathology.

[42]  E. McCulloch.  Stem cells in normal and leukemic hemopoiesis (Henry Stratton Lecture, 1982) , 1983 .

[43]  M. Housset,et al.  Small doses of ARA‐C in the treatment of acute myeloid leukaemia: differentiation of myeloid leukaemia cells? , 1982, British journal of haematology.

[44]  R. Gallo,et al.  Induction of differentiation of human promyelocytic leukemia cells (HL-60) by nucleosides and methotrexate. , 1981, Journal of the National Cancer Institute.

[45]  H. Koeffler,et al.  Phorbol diester-induced macrophage differentiation of leukemic blasts from patients with human myelogenous leukemia. , 1980, The Journal of clinical investigation.